Angus B J, Smith M D, Suputtamongkol Y, Mattie H, Walsh A L, Wuthiekanun V, Chaowagul W, White N J
Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok 10400, Thailand.
Br J Clin Pharmacol. 2000 May;49(5):445-52. doi: 10.1046/j.1365-2125.2000.00179.x.
Experimental studies have suggested that constant intravenous infusion would be preferable to conventional intermittent bolus administration of beta-lactam antibiotics for serious Gram-negative infections. Severe melioidosis (Burkholderia pseudomallei infection) carries a mortality of 40% despite treatment with high dose ceftazidime. The aim of this study was to measure the pharmacokinetic and pharmacodynamic effects of continuous infusion of ceftazidime vs intermittent bolus dosing in septicaemic melioidosis.
Patients with suspected septicaemic melioidosis were randomised to receive ceftazidime 40 mg kg-1 8 hourly by bolus injection or 4 mg kg-1 h-1 by constant infusion following a 12 mg kg-1 priming dose to perform estimation of pharmacokinetic and pharmacodynamic parameters.
Of the 34 patients studied 16 (59%) died. Twenty patients had cultures positive for B. pseudomallei of whom 12 (60%) died. The median MIC90 of B. pseudomallei was 2 mg l-1, giving a target concentration CT, of 8 mg l-1. The median (range) estimated total apparent volume of distribution, systemic clearance and terminal elimination half-lives of ceftazidime were 0.468 (0.241-0.573) l kg-1, 0.058 (0.005-0.159) l kg-1 h-1 and 7.74 (1.95-44.71) h, respectively. Clearance of ceftazidime and creatinine clearance were correlated closely (r = 0. 71; P < 0.001) and there was no evidence of significant nonrenal clearance.
Simulations based on these data and the ceftazidime sensitivity of the B. pseudomallei isolates indicated that administration by constant infusion would allow significant dose reduction and cost saving. With conventional 8 h intermittent dosing to patients with normal renal function, plasma ceftazidime concentrations could fall below the target concentration but this would be unlikely with a constant infusion. Correction for renal failure which is common in these patients is Clearance = k * creatinine clearance where k = 0.072. Calculation of a loading dose gives median (range) values of loading dose, DL of 3.7 mg kg-1 (1. 9-4.6) and infusion rate I = 0.46 mg kg h-1 (0.04-1.3) (which equals 14.8 mg kg-1 day-1). A nomogram for adjustment in renal failure is given.
实验研究表明,对于严重革兰氏阴性菌感染,持续静脉输注β-内酰胺类抗生素比传统的间歇性大剂量注射给药更为可取。尽管使用高剂量头孢他啶治疗,严重类鼻疽(假鼻疽伯克霍尔德菌感染)的死亡率仍为40%。本研究的目的是测量在败血症性类鼻疽中持续输注头孢他啶与间歇性大剂量给药的药代动力学和药效学效应。
疑似败血症性类鼻疽患者被随机分为两组,一组接受每8小时静脉推注40mg/kg头孢他啶,另一组在给予12mg/kg的负荷剂量后,以4mg/kg·h的速度持续输注,以进行药代动力学和药效学参数的评估。
在研究的34例患者中,16例(59%)死亡。20例患者的假鼻疽伯克霍尔德菌培养呈阳性,其中12例(60%)死亡。假鼻疽伯克霍尔德菌的MIC90中位数为2mg/L,目标浓度CT为8mg/L。头孢他啶的估计总体表观分布容积、全身清除率和终末消除半衰期的中位数(范围)分别为0.468(0.241 - 0.573)L/kg、0.058(0.005 - 0.159)L/kg·h和7.74(1.95 - 44.71)h。头孢他啶清除率与肌酐清除率密切相关(r = 0.71;P < 0.001),且没有明显非肾清除的证据。
基于这些数据和假鼻疽伯克霍尔德菌分离株对头孢他啶的敏感性进行的模拟表明,持续输注给药可显著降低剂量并节省成本。对于肾功能正常的患者采用传统的8小时间歇性给药时,血浆头孢他啶浓度可能会降至目标浓度以下,但持续输注则不太可能出现这种情况。这些患者常见肾功能衰竭的校正公式为清除率 = k×肌酐清除率,其中k = 0.072。负荷剂量的计算得出负荷剂量DL的中位数(范围)值为3.7mg/kg(1.9 - 4.6),输注速率I = 0.46mg/kg·h(0.04 - 1.3)(相当于14.8mg/kg·天)。给出了肾功能衰竭时调整的列线图。